No Data
No Data
Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference
Gain Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Gain Therapeutics Excels in Neurodegenerative Drug Trials
Gain Therapeutics Presents Preclinical Data on GT-02287
Express News | Gain Therapeutics Announced The Presentation Of New Evidence Supporting The Disease-modifying Activity Of Gt-02287 In Preclinical Animal Models Of Both GBA-1 And Idiopathic Parkinson's Disease
Gain Therapeutics to Participate at Upcoming Investor Conferences